Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Am J Gastroenterol. 2022 Nov 1;117(11):1764-1771. doi: 10.14309/ajg.0000000000001935. Epub 2022 Aug 12.
Despite societal recommendations supporting Barrett's esophagus (BE) screening, it is unknown what proportion of eligible patients is screened in primary care. We assessed the proportion of BE screening- eligible patients evaluated in the primary care setting receiving upper esophagogastroduodenoscopy (EGD) and identified factors associated with undergoing EGD.
This was a retrospective study of BE screening-eligible patients, as defined by the American College of Gastroenterology's BE guidelines, in a multipractice healthcare network consisting of 64 internal medicine practices and 94 family medicine (FM) practices. The proportion undergoing EGD, prevalence of BE and esophageal adenocarcinoma (EAC) in this group, and patient and provider factors associated with undergoing EGD were assessed. Multivariable logistic regression was performed to identify independent predictors of undergoing EGD.
Of 1,127 screening-eligible patients, the mean age was 65.2 ± 8.6 years; 45% were obese; and 61% were smokers. Seventy-three percent were seeing FM; 94% were on proton pump inhibitors; and 44% took ≥1 gastroesophageal reflux disease (GERD) medication. Only 39% of patients (n = 436) had undergone EGD. The overall prevalence of BE or EAC was 9.9%. Of 39 (9%) referred for BE screening as the primary indication, BE/EAC prevalence was 35.1%. Factors associated with increased odds of having EGD were symptomatic GERD despite treatment (odds ratio [OR] 12.1, 95% confidence interval [CI] 9.1-16.3), being on ≥1 GERD medication (OR 1.4, 95% CI 1.0-1.9), and being an FM patient (OR 1.5, 95% CI 1.1-2.1).
In this large, primary care population, only 39% of screening-eligible patients underwent EGD. Most of the examinations were triggered by refractory symptoms rather than screening referrals, highlighting a need for improved dissemination and implementation of BE screening.
尽管社会建议支持 Barrett 食管(BE)筛查,但尚不清楚在初级保健中筛查了多少符合条件的患者。我们评估了在初级保健环境中评估的 BE 筛查合格患者中接受上食管胃十二指肠镜检查(EGD)的比例,并确定了与进行 EGD 相关的因素。
这是一项针对符合美国胃肠病学院 BE 指南定义的 BE 筛查合格患者的回顾性研究,这些患者来自一个由 64 个内科实践和 94 个家庭医学(FM)实践组成的多实践医疗网络。评估了该组患者中接受 EGD 的比例、BE 和食管腺癌(EAC)的患病率,以及与接受 EGD 相关的患者和提供者因素。进行多变量逻辑回归以确定接受 EGD 的独立预测因素。
在 1127 名筛查合格的患者中,平均年龄为 65.2±8.6 岁;45%为肥胖;61%为吸烟者。73%的患者在看 FM;94%的患者在服用质子泵抑制剂;44%的患者服用≥1 种胃食管反流病(GERD)药物。只有 39%的患者(n=436)接受了 EGD。总的 BE 或 EAC 患病率为 9.9%。在作为主要指征进行 BE 筛查的 39 名(9%)患者中,BE/EAC 的患病率为 35.1%。与接受 EGD 几率增加相关的因素包括尽管接受了治疗,但 GERD 症状仍存在(比值比[OR] 12.1,95%置信区间[CI] 9.1-16.3)、服用≥1 种 GERD 药物(OR 1.4,95% CI 1.0-1.9)和是 FM 患者(OR 1.5,95% CI 1.1-2.1)。
在这个大型的初级保健人群中,只有 39%的筛查合格患者接受了 EGD。大多数检查是由难治性症状引发的,而不是筛查转诊,这突出表明需要改进 BE 筛查的传播和实施。